Financial Performance - Revenue for Q1 2021 was SGD 2,993,000, a decrease of 31.5% compared to SGD 4,377,000 in Q1 2020[16] - Gross profit for Q1 2021 was SGD 831,000, down from SGD 987,000 in Q1 2020, reflecting a gross margin of approximately 27.8%[16] - Profit before taxation increased to SGD 205,000 in Q1 2021, compared to SGD 112,000 in Q1 2020, representing an 83.0% increase[16] - Net income for the period was SGD 175,000, significantly higher than SGD 67,000 in Q1 2020, marking a 160.4% increase[16] - Earnings per share for Q1 2021 was 0.02 cents, up from 0.01 cents in Q1 2020[16] - Other income for Q1 2021 was SGD 112,000, compared to SGD 33,000 in Q1 2020, indicating a substantial increase[16] - The company reported a total comprehensive income of SGD 175,000 for the period, compared to SGD 67,000 in the previous year[16] - Revenue from tissue products was SGD 2,609,000, down 32.8% from SGD 3,879,000 in the same period last year[53] - Profit attributable to equity holders of the Company for Q1 2021 was SGD 175,000, compared to SGD 67,000 in Q1 2020, representing a significant increase[77] - Revenue for the Relevant Period was $3.0 million, a decrease of 31.6% compared to $4.4 million in the Previous Period[87] - Profit for the Relevant Period was $175,000, an increase of 161.2% compared to $67,000 in the Previous Period[95] Expenses and Cost Management - Selling and distribution expenses decreased to SGD 350,000 in Q1 2021 from SGD 434,000 in Q1 2020, a reduction of 19.4%[16] - Administrative expenses were SGD 384,000 in Q1 2021, down from SGD 403,000 in Q1 2020, reflecting a decrease of 4.7%[16] - Staff costs for Q1 2021 were SGD 518,000, a decrease from SGD 565,000 in Q1 2020[57] - The cost of inventories for Q1 2021 was SGD 1,933,000, a decrease of 39.5% from SGD 3,197,000 in Q1 2020[57] - Cost of sales was $2.2 million, a decrease of 36.2% from $3.4 million in the Previous Period[92] - Selling and distribution expenses amounted to $350,000, a decrease of 19.4% from $434,000 in the Previous Period[95] - Administrative expenses were $384,000, a slight decrease of 4.7% compared to $403,000 in the Previous Period[95] Corporate Governance and Compliance - The company has adopted the Corporate Governance Code to ensure proper regulation of business activities and decision-making processes[148] - The Audit Committee consists of three independent non-executive Directors, who reviewed the unaudited condensed consolidated financial statements for the Relevant Period[153] - The Audit Committee consists of three independent non-executive directors, including Ms. Chua Joo Gek, Mr. Ng Boon Cheow Freddie, and Mr. Tog Chek Soon, with Ms. Chua Joo Gek serving as the chairperson[155] - The company has maintained compliance with the Securities and Futures Ordinance regarding the registration of interests[131] - The company has disclosed all relevant interests and positions held by its directors and chief executives as required by the GEM Listing Rules[131] Strategic Outlook and Market Position - The company is optimistic about recovering revenue as Singapore entered phase three of reopening on December 28, 2020[87] - The company will continue to evaluate development opportunities to strengthen its competitive advantage and market position[87] - The company aims to achieve sustainable growth and greater returns for shareholders[87] - The company expects a revenue growth guidance of BB% for the upcoming quarter, driven by new product launches and market expansion strategies[172] - New product development includes the introduction of a premium tissue line, projected to contribute CC% to overall sales in the next fiscal year[171] - The company is exploring market expansion opportunities in Southeast Asia, targeting a market share increase of DD% by the end of 2022[170] - A strategic acquisition of a local competitor is anticipated to enhance the company's market position and is expected to close by the end of Q3 2021[169] - The company is considering strategic acquisitions to bolster its portfolio, with potential targets identified in the industry[178] Sustainability Initiatives - The management highlighted a focus on sustainability initiatives, with a goal to reduce carbon emissions by HH% over the next three years[170] - The company emphasized its commitment to sustainability, with plans to invest S$FF million in eco-friendly initiatives[178] Shareholder Information - Mr. Chua Liang Sie holds a long position of 576,000,000 shares in YJH Group Limited, representing a significant corporate interest[121] - Ms. Chua Joo Gek and Mr. Chua Liang Chui each hold 576,000,000 shares in YJH Group Limited, indicating a concert party agreement among the three[125] - The ownership distribution in YJH Group Limited is approximately 65.52% by Mr. Chua Liang Sie, 17.24% by Ms. Chua Joo Gek, and 17.24% by Mr. Chua Liang Chui[116] - The total number of shares held by the concert party is 576,000,000, which constitutes a substantial interest in the company[121] - As of the end of the relevant period, no other directors or chief executives have registered interests in the shares or debentures of the company[131] - The substantial shareholders' interests are recorded in the register required to be kept under Section 336 of the SFO[122] Risk Factors and Forward-Looking Statements - The report includes forward-looking statements regarding the Group's financial conditions and operational performance, which may differ materially from actual results due to known and unknown risks[155] - The report outlines the impact of COVID-19 on operations, including measures taken to mitigate risks associated with the pandemic[162] - The company reported a significant increase in revenue for Q1 2021, reaching approximately S$XX million, representing a YY% growth compared to the previous quarter[178] - User data showed an increase in active users by ZZ%, indicating strong customer engagement and retention strategies[178]
日光控股(08451) - 2021 Q1 - 季度财报